StockData
Corbus Pharmaceuticals Holdings, Inc. logo

Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock

CRBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$2.75−0.26 (-8.80%)

Close on Nov 18, 2026Market cap $53.09MP/E –Yield –

Corbus Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Corbus Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$86.67M. For fiscal 2025 it was -$64.49M. The highest annual figure on record is -$366.72K in fiscal 2013.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$64.49M–
FY2024Dec 31, 2024-$41.79M–
FY2023Dec 31, 2023-$36.10M–
FY2022Dec 31, 2022-$37.54M–
FY2021Dec 31, 2021-$48.18M–
FY2020Dec 31, 2020-$99.69M–
FY2019Dec 31, 2019-$45.72M–
FY2018Dec 31, 2018-$30.07M–
FY2017Dec 31, 2017-$27.80M–
FY2016Dec 31, 2016-$13.57M–
FY2015Dec 31, 2015-$4.62M–
FY2014Dec 31, 2014-$2.36M–
FY2013Dec 31, 2013-$366.72K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$29.63M–
Q1 FY2026Mar 31, 2026-$25.57M–
Q4 FY2025Dec 31, 2025-$15.92M–
Q3 FY2025Sep 30, 2025-$15.55M–
Q2 FY2025Jun 30, 2025-$16.60M–
Q1 FY2025Mar 31, 2025-$16.42M–
Q4 FY2024Dec 31, 2024-$10.94M–
Q3 FY2024Sep 30, 2024-$13.94M–
Q2 FY2024Jun 30, 2024-$8.94M–
Q1 FY2024Mar 31, 2024-$7.97M–
Q4 FY2023Dec 31, 2023-$6.01M–
Q3 FY2023Sep 30, 2023-$7.18M–
Q2 FY2023Jun 30, 2023-$7.80M–
Q1 FY2023Mar 31, 2023-$15.11M–
Q4 FY2022Dec 31, 2022-$7.45M–
Q3 FY2022Sep 30, 2022-$7.25M-945.4%
Q2 FY2022Jun 30, 2022-$12.23M–
Q1 FY2022Mar 31, 2022-$10.62M–
Q4 FY2021Dec 31, 2021-$9.70M–
Q3 FY2021Sep 30, 2021$856.95K–
Q2 FY2021Jun 30, 2021-$17.53M–
Q1 FY2021Mar 31, 2021-$21.81M–
Q4 FY2020Dec 31, 2020-$18.22M–
Q3 FY2020Sep 30, 2020-$27.25M–
Q2 FY2020Jun 30, 2020-$26.61M–
Q1 FY2020Mar 31, 2020-$27.60M-367.5%
Q4 FY2019Dec 31, 2019-$22.56M–
Q3 FY2019Sep 30, 2019-$17.09M–
Q2 FY2019Jun 30, 2019-$16.39M–
Q1 FY2019Mar 31, 2019$10.32M–
Q4 FY2018Dec 31, 2018-$14.06M–
Q3 FY2018Sep 30, 2018-$8.85M–
Q2 FY2018Jun 30, 2018-$5.56M–
Q1 FY2018Mar 31, 2018-$1.60M–
Q4 FY2017Dec 31, 2017-$9.11M–
Q3 FY2017Sep 30, 2017-$6.33M–
Q2 FY2017Jun 30, 2017-$5.71M–
Q1 FY2017Mar 31, 2017-$6.64M–
Q4 FY2016Dec 31, 2016-$5.48M–
Q3 FY2016Sep 30, 2016-$3.05M–

More Corbus Pharmaceuticals figures

See a number that looks wrong?